Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.
Medpace Holdings, Inc. earns a Q-Score of 100/100 from the StockConviction analysis engine. Current valuation zone: Undervalued.
🔒 Estimated value and discount % — Premium account required
Full analysis
Access the full analysis
Estimated value, discount %, detailed conviction signals, history and zone alerts.